A 6-week multicenter, randomized, double-blind, placebo-controlled, parallel group effficacy trial of 2 different dose regimens of lumiracoxib (100 mg bid and 200 mg od)in patients with primary knee osteoarthritis using naproxen 500 mg bid as a positive control

Trial Profile

A 6-week multicenter, randomized, double-blind, placebo-controlled, parallel group effficacy trial of 2 different dose regimens of lumiracoxib (100 mg bid and 200 mg od)in patients with primary knee osteoarthritis using naproxen 500 mg bid as a positive control

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs Lumiracoxib; Naproxen
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top